Clinical Trials Browser

Interventional × lorlatinib × Clear all

NCT03737994 2026-03-18

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2 Active not recruiting

10 enrolled 17 charts

Lung Neoplasms

NCT06333899 2026-03-12

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Phase EARLY_PHASE1 Recruiting

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Phase 3 Recruiting

Neuroblastoma, Ganglioneuroblastoma

NCT07415005 2026-02-17

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Advanced Non-Small Cell Lung Cancer

NCT06007937 2026-02-05

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT05740943 2026-01-20

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05297890 2025-12-23

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

NCT05144997 2025-12-17

Lorlatinib Continuation Study

Phase 4 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03052608 2025-11-25

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Phase 3 Active not recruiting

296 enrolled 28 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03909971 2025-11-05

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Phase 2 Completed

109 enrolled 33 charts

Carcinoma, Non-Small-Cell Lung

NCT04621188 2025-09-24

Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

Phase 2 Active not recruiting

Non Small Cell Lung Cancer Metastatic

NCT03107988 2025-09-15

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Phase 1 Completed

65 enrolled 38 charts

Neuroblastoma

NCT07083687 2025-07-24

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04362072 2025-06-11

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

Phase 4 Completed

71 enrolled 26 charts

Carcinoma

NCT04111705 2025-04-01

ORAKLE

Phase 2 Completed

Non Small Cell Lung Cancer Metastatic

NCT06858410 2025-03-05

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

Phase 3 Not yet recruiting

Adenocarcinoma of Lung

NCT04541706 2024-12-20

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Phase 4 Completed

100 enrolled 10 charts

Advanced Non-Small Cell Lung Cancer

NCT06682884 2024-11-12

NEOLORA

Phase 2 Not yet recruiting

Neoadjuvant Non-Small Cell Lung Cancer

NCT04127110 2024-11-05

ALKALINE

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04800822 2024-10-22

PF-07284892 in Participants With Advanced Solid Tumors

Phase 1 Terminated

CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT05014464 2024-09-20

ATPase

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT01970865 2024-08-12

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1/2 Completed

364 enrolled 89 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03726333 2024-06-21

Hepatic Impairment Study for Lorlatinib in Cancer Patients

Phase 1 Terminated

1 enrolled 3 charts

Lung Neoplasms, Neoplasms

NCT06378892 2024-04-23

ALK-PPL

Phase 2 Recruiting

Non Small Cell Lung Cancer Metastatic

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT06092086 2023-10-23

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Phase 2 Recruiting

ALK Positive Non-small Cell Lung Cancer

NCT03505554 2023-08-07

CRU3

Phase 2 Unknown

Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT03612154 2022-04-06

Study of Lorlatinib in ROS1 Rearranged NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03439215 2021-07-19

PFROST

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Phase 1/2 Unknown

Lung Neoplasms, Recurrence

NCT02927340 2021-03-09

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms